FA Symposium 2025: Friedreich's Ataxia Drug Development Pipeline Update and Q&A (Session #7)
Автор: Friedreich's Ataxia Research Alliance
Загружено: 2025-10-30
Просмотров: 274
Описание:
Moderated by Jennifer Farmer, Chief Executive Officer, FARA
Representatives from: Biogen, Design Therapeutics, Larimar Therapeutics, Lexeo Therapeutics, PTC Therapeutics, and Solid Biosciences
FARA's Mission is to marshal and focus the resources and relationships needed to cure Friedreich's Ataxia (FA) by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases.
Friedreich’s Ataxia is a debilitating, life-shortening, degenerative neuro-muscular disorder. About one in 50,000 people in the United States have Friedreich's Ataxia.
Subscribe to FARA's YouTube channel / fara1998
Follow FARA on Facebook / curefa
Follow FARA on Instagram / curefa_org
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
